An open-label expanded-access trial of bendamustine in patients with rituximab-refractory indolent non-Hodgkin lymphoma or previously untreated chronic lymphocytic leukemia: BEND-ACT

BACKGROUND: Bendamustine is a bifunctional alkylating agent with unique properties that distinguish it from other agents in its class. Bendamustine is used as monotherapy or in combination with other agents to treat patients with non-Hodgkin lymphoma (nhl) and chronic lymphocytic leukemia (cll). MET...

詳細記述

保存先:
書誌詳細
出版年:Curr Oncol
主要な著者: Kouroukis, C.T., Crump, M., MacDonald, D., Larouche, J.F., Stewart, D.A., Johnston, J., Sauvageau, S., Beausoleil, E., Sage, P., Dubois, S.G., Christofides, A., Di Clemente, S., Sehn, L.
フォーマット: Artigo
言語:Inglês
出版事項: Multimed Inc. 2015
主題:
Original Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4530811/
https://ncbi.nlm.nih.gov/pubmed/26300664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.22.2431
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料